MedPath

Effect of dRAST on Treatment for Bacteremia in Patients With Hematologic Diseases

Not Applicable
Completed
Conditions
Hematologic Diseases
Bacteremia Sepsis
Interventions
Diagnostic Test: dRAST
Diagnostic Test: Current standard method
Registration Number
NCT03611257
Lead Sponsor
Seoul National University Hospital
Brief Summary

The purpose of this study is to evaluate whether the use of direct rapid antibiotic susceptibility test (dRAST), in addition to the current standard antibiotic susceptibility test, can increase the proportion of patients with hematologic disease who received appropriate antibiotics in early period of bacteremia.

Detailed Description

* patients with hematologic diseases who have high risk of bacteremia, because of immune suppression treatment or intensive chemotherapy or bone marrow transplantation which these patients had received, will be recruited in tertiary referral medical centers.

* All the participants will be randomly assigned into either dRAST group or current standard antibiotic susceptibility test group.

* All the participants in the both arms will receive antimicrobial stewardship by infectious disease specialists. Antimicrobial stewardship will be performed at each timepoint of Gram stain results reporting, dRAST results reporting, and current method reporting.

* Target numbers are 58 and 58, respectively.

* All the participants will be monitored for general medical conditions such as vital sign and response to antibiotic treatment by infectious disease specialists for 1 week.

* The percentage of patients who received optimal targeted antibiotics 72 hours after blood collection for blood culture will be evaluated.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
116
Inclusion Criteria
  • Patients who are expected to be admitted for more than 2 days due to treatment or complications of hematologic diseases (acute leukemia, chronic leukemia, myelodysplastic syndrome, lymphoma, multiple myeloma, aplastic anemia, etc.) in Seoul National University Hospital.
  • Patients with confirmed bacteremia
  • Patients who can understand the details of the clinical trial's explanation and provide the written consent
Exclusion Criteria
  • Patients who are expected to stay in the hospital within 2 days
  • Patients without bacteremia during hospitalization
  • Patients who show fungemia without evidence of bacteremia

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
dRASTdRASTHematologic patients with bacteremia will receive antibiotics based on "dRAST" results.
Current standard methodCurrent standard methodHematologic patients with bacteremia will receive antibiotics based on current standard method results.
Primary Outcome Measures
NameTimeMethod
Percentage of patients receiving optimal targeted antibiotics 72 hours after blood collection for blood culture72 hour after blood culture collection

The percentage of patients receiving optimal targeted antibiotics antibiotics which is defined as most effective and narrowest antibiotics based on susceptibility testing results, 72 hours after blood collection for blood culture

Secondary Outcome Measures
NameTimeMethod
Amount of broad-spectrum antibiotics useTime from first blood culture collection up to 1 week

The duration of use of major antibiotics (vancomycin, carbapenem)

Time to defervescenceTime from first blood culture collection up to 1 month

Time from the time of blood culture collection to the time of fever resolution

Time to optimal targeted antibioticsTime from first blood culture collection up to 1 month

The time to the optimal targeted antibiotics administration after blood culture collection

Percentage of patients receiving unnecessary broad spectrum antibiotics 72 hours after72 hour after blood culture collection

The percentage of patients receiving unnecessary broad spectrum antibiotics which is defined as administration of antibiotics to which organisms were susceptible, but had broad-spectrum activity requiring de-escalation or discontinuing administration, 72 hours after blood collection for blood culture

proportion of positive blood culture 48 hours after first blood cultureTime from blood culture collection up to 1 month

proportion of positive blood culture 48 hours after first blood culture

Percentage of patients receiving ineffective antibiotics 72 hours after72 hour after blood culture collection

The percentage of patients receiving ineffective antibiotics which is defined if the organisms were not susceptible, 72 hours after blood collection for blood culture

30-day mortality rate related with bacteremiaTime from blood culture collection up to 30-day

30-day mortality rate related with bacteremia

Percentage of patients receiving optimal targeted antibiotics 48 hours after48 hour after blood culture collection

The percentage of patients receiving optimal targeted antibiotics antibiotics which is defined as most effective and narrowest antibiotics based on susceptibility testing results, 48 hours after blood collection for blood culture

Percentage of patients receiving unnecessary broad spectrum antibiotics 48 hours after48 hour after blood culture collection

The percentage of patients receiving unnecessary broad spectrum antibiotics which is defined as administration of antibiotics to which organisms were susceptible, but had broad-spectrum activity requiring de-escalation or discontinuing administration, 48 hours after blood collection for blood culture

Percentage of patients receiving ineffective antibiotics 48 hours after48 hour after blood culture collection

The percentage of patients receiving ineffective antibiotics which is defined if the organisms were not susceptible, 48 hours after blood collection for blood culture

Trial Locations

Locations (1)

Seoul National University Hospital

🇰🇷

Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath